Anthracycline Market Report 2024: Strategies And Recent Developments | Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA

The Business Research Company offers in-depth market insights through Anthracycline Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The anthracycline market size has grown strongly in recent years. It will grow from $1.41 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of cancer, growing demand for personalized cancer treatment, rising awareness of the benefits of anthracyclines, investment in anthracycline .

The anthracycline market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing awareness about cancer treatment, investments in research and development for cancer treatments, growing demand for effective and convenient treatments for cancer, growing number of screening programs for cancer, government initiatives. Major trends in the forecast period include advancements in anthracycline formulations, combination therapies, cardioprotective strategies, developing biosimilars of anthracyclines.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12914&type=smp

Market Segmentation:
The main types of drugs included in anthracycline are daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin. Daunorubicin is an anthracycline chemotherapy agent that inhibits DNA and RNA synthesis by intercalating into the DNA helix and inhibiting topoisomerase II, leading to cell cycle arrest and apoptosis in rapidly dividing cells. Various types of dosages are available, including powder, capsule, solution, injection, suspension and others, which are used in several applications, including acute lymphocytic leukemia, acute myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, bladder cancer, breast cancer and others. Various end users include hospitals, home care, specialty clinics and others.
Anthracycline Global Market Report 2023 provides data on the global anthracycline market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors' revenues, profiles and market shares. The anthracycline market report identifies opportunities and strategies based on market trends and leading competitors' approaches.

Major Driver - Rising Cancer Prevalence Fuels Growth In The Anthracycline Market
The increasing prevalence of cancer is expected to propel the growth of the anthracycline market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries and either spread to other organs or invade neighboring body parts. Anthracycline, a class of chemotherapy drugs, plays a significant role in cancer treatment as it prevents cell division by disrupting the structure of the DNA and terminating its function. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase from 1.8 million new cancer cases diagnosed in 2020. Further, around 609,820 cancer-related deaths are anticipated in 2023, with an expected 606,520 in 2020. Therefore, the increasing prevalence of cancer is driving the growth of the anthracycline market.

Competitive Landscape:
Major players in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd., Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

Top Trend - Innovative Approaches And Generic Offerings Shape The Anthracycline Production
Major companies operating in the anthracycline market are focused on developing innovative novel drugs such as Doxorubicin Liposome Injection to sustain their position in the market. For instance, in October 2021, Padagis LLC, an Israel-based pharmaceutical company that produces generic prescription medicines, announced the FDA's (Food and Drug Administration) approval and launch of a generic version of Doxil (Doxorubicin Liposome Injection) with an AB rating. The company has launched the drug through a partnership with Ayana Pharma Ltd., an Israel-based developer of liposomal drugs for cancer therapeutics. Doxil liposome injection is an anthracycline topoisomerase inhibitor used to treat ovarian cancer, Kaposi's sarcoma related to AIDS (acquired immunodeficiency syndrome) and multiple myeloma. This treatment functions by inhibiting or decelerating the proliferation of cancerous cells. It is introduced into a vein through an injection lasting 30-60 minutes or more.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Anthracycline Market Characteristics
3. Anthracycline Market Trends And Strategies
4. Anthracycline Market - Macro Economic Scenario
5. Anthracycline Market Size And Growth
…..
27. Anthracycline Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.